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Cyclosporin ACyclophilins are a family of peptidyl-prolyl cis–trans isomerases whose enzymatic activity can be inhibited
by cyclosporin A. Sixteen cyclophilins have been identiﬁed in humans, and cyclophilin D is a unique isoform
that is imported into the mitochondrial matrix. Here we shall (i) review the best characterized functions of
cyclophilin D in mitochondria, i.e. regulation of the permeability transition pore, an inner membrane channel
that plays an important role in the execution of cell death; (ii) highlight new regulatory interactions that are
emerging in the literature, including the modulation of the mitochondrial F1FO ATP synthase through an
interaction with the lateral stalk of the enzyme complex; and (iii) discuss diseases where cyclophilin D plays
a pathogenetic role that makes it a suitable target for pharmacologic intervention.s, cyclosporin; CyP, cyclophilin;
yl cis–trans isomerase; PTP,
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Cyclophilins (CyPs) are ubiquitous proteins endowed with
peptidyl-prolyl cis–trans isomerase (PPIase) activity [1,2] that have
been highly conserved during evolution. CyPs can be identiﬁed in the
genomes of mammals, plants, insects, fungi and bacteria; they all
share a common domain of approximately 109 amino acids, the CyP-
like domain [3]. In humans 16 unique CyPs have been found [3], with
CyPA representing the prototype of the family [1,2]. After binding to
the CyP ligand cyclosporin (Cs) A, the PPIase activity is inhibited
[4], and the CsA/CyPA complex binds to and inhibits the cytosolic
phosphatase calcineurin [5] resulting in immunosuppression [6,7].
Together with the FK506-binding proteins (FKBP, structurally
unrelated PPIases that share with CyPs the ability to inhibit
calcineurin after binding their cognate inhibitory ligand FK506),
they constitute the family of immunophilins [8]. Work with mutants
of human CyPA has clearly separated the PPIase activity of the proteinfrom CsA binding and calcineurin inhibition [9], suggesting that CyPs
have speciﬁc cellular functions that may be of importance for a variety
of processes relevant to human disease [3].
The evolutionary conservation of the PPIase activity among species
suggests that this can be an important function of the CyPs and FKBPs
[10], as shown by the Drosophila NinaA PPIase, which serves as a
chaperone for speciﬁc rhodopsin isoforms [11]. Yet, and somewhat
surprisingly, Saccharomyces cerevisiae mutants lacking all 12 yeast
immunophilins were viable, and the phenotype of the dodecuplet
mutant resulted from simple addition of the subtle phenotypes of
each individual mutation [12]. This striking ﬁnding led these authors
to conclude that CyPs and FKBPs do not play an essential general role
in protein folding, and to propose that each CyP and FKBP insteadmay
regulate a restricted number of unique partner proteins [12]. In
keeping with this prediction, CyPs have been shown in recent years to
be involved in a variety of pathophysiological processes including
inﬂammation and vascular dysfunction [13–17], wound healing [18],
innate immunity to HIV [19], hepatitis C infection [20], host–parasite
interactions [21], tumor biology [22] and regulation of the mitochon-
drial permeability transition pore (PTP) which is mediated by the
mitochondrial isoform of the enzyme, CyPD [23–26]. The existence of
speciﬁc functions is also suggested by the presence of tissue- and
organelle-speciﬁc isoforms characterized by the combination of the
signature CyP domain with the proper targeting and/or retention
sequence(s) [3].
Fig. 1. Modulation of the permeability transion pore by CyPD and Pi. The CyPD-bound
form of the PTP displays a higher probability of opening (right); addition of CsA
displaces CyPD and unmasks a cryptic site for Pi (center); if the Pi concentration is
sufﬁciently high, Pi binding decreases the probability of pore opening (left), in a
reaction that can be readily reversed if the Pi concentration decreases.
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Cs are cyclic undecapeptides produced by several fungal taxa
including the common strain Tolypocladium inﬂatum. CsA is the most
studied [27]; its ability to prevent the immune response has
revolutionized medicine, allowing organ transplantion to become a
standard therapeutic practice. Interaction of CsA with cytosolic CyPA
generates a complex that acquires the ability to bind to, and inhibit,
the cytosolic, Ca2+-activated phosphatase calcineurin [5]; as a
consequence of calcineurin inhibition, its substrate phospho-NFAT is
no longer dephosphorylated and therefore unable to translocate to
the nucleus and trigger the IL-2-dependent activation of the immune
response against the transplant [6,7]. Recently, an important
discovery has been made showing that translocation of the cytosolic
pro-ﬁssion protein Drp1 to mitochondria requires its calcineurin-
dependent dephosphorylation at Ser637 that is inhibited by CsA [28].
Thus, CsA also affects mitochondrial shape and function via calci-
neurin inhibition independent of its interactions with matrix CyPD
(see below), a concept that should be taken into account when
interpreting the complex effects of CsA onmitochondrial function and
cell survival [29]. Separation of the calcineurin-dependent and
-independent effects of Cs has been greatly helped by non-
immunosuppressive analogs of CsA (such as MeVal-4-Cs, NIM811
and Debio 025) that maintain the ability to bind to, and inhibit CyPs
but not calcineurin [24,30–32]. Like Cs these drugs likely inhibit all
CyPs to varying degrees [3,26], a point that should be kept in mind
when the mitochondrial effects of these molecules are evaluated. A
recent study has identiﬁed a small-molecule inhibitor based on aryl 1-
indanylketones that discriminates between CyPA and CyPB in vitro, a
proof of principle that holds great promise for the development of
isoform-speciﬁc CyP inhibitors [33]. The rapidly growing ﬁeld of CyP
biochemistry, pharmacology and pathophysiology is beyond the
scope of this article, but the interested reader can ﬁnd further
information in recent reviews [3,34,35].
3. Cyclophilin D and the permeability transition
CyPD is the uniquemitochondrial isoform of CyP in mammals [23–
25]. Its identiﬁcation was prompted by the demonstration that CsA
affects mitochondrial Ca2+ ﬂuxes [36] through an effect that could be
traced to desensitization of the PTP [37–40], an innermembrane high-
conductance channel whose molecular composition remains an
unanswered question [41–45]. The PTP plays a key role in cell death
and has proved to be a viable target for therapeutic intervention in a
variety of diseases, most notably ischemia–reperfusion injury of the
heart and brain, muscular dystrophies, neurodegeneration and cancer
[41–45]. Genetic ablation of the Ppif gene (which encodes for CyPD) in
the mouse has demonstrated that CyPD is the mitochondrial receptor
for CsA, and that it is responsible for modulation of the PTP but not a
structural pore component [46–49]. As discussed more in detail
elsewhere [42], the effect of CsA on the PTP is best described as
“desensitization” in the sense that the PTP becomes more resistant to
opening after the uptake of Ca2+ and Pi in standard in vitro assays in
isolated mitochondria; yet pore opening readily takes place for Ca2+–
Pi loads that are about twice those required in wild-type mitochon-
dria. A major step forward in our mechanistic understanding of the
role of CyPD in PTP modulation has been the discovery that CyPD
ablation (or treatment with CsA) unmasks an inhibitory site for Pi,
which is the actual PTP desensitizing agent [50]. Unless Pi is present,
the sensitivity of the PTP to Ca2+ and to other agents of pathophys-
iological relevance is identical in naïve and CsA-treated wild type
mitochondria, as well as in CyPD-null mitochondria. This ﬁnding has
important implications for our understanding of PTP regulation.
Indeed, as also noted elsewhere [50] (i) it is fortunate that Pi was
included in mitochondrial swelling assays of PTP in vitro, so that the
desensitizing effect of CsA was not missed; and (ii) the Pi-dependenceof PTP inhibition by CsA and CyPD ablationmay be just one example of
the factors that control the PTP sensitivity to inhibitors in situ. Thus,
extreme caution should be exerted when results from in vitro studies
are extrapolated to the status of the PTP in vivo. Fig. 1 presents a
scheme where the effects of CyPD and Pi on the PTP are summarized.
In the CyPD-bound state the Pi site is not available, and the PTP favors
the open conformation (right). Addition of CsA (or CyPD ablation)
unmasks the Pi binding site by removing CyPD (middle); if the free
[Pi] concentration is high enough [50], Pi binding to the PTP lowers
the open probability (left) in a reaction that is readily reversible if the
[Pi] concentration decreases. Although no endogenous ligands of
CyPD mimicking the effects of CsA are currently known, other PTP
(de)sensitizers might act by favoring CyPD association or dissociation.
Indeed, the existence of additional effector sites on the PTP is strongly
suggested by the large variety of PTP inducers and inhibitors [51].4. Cyclophilin D interactions with other proteins
An interaction of CyPD with the adenine nucleotide translocator
(ANT) has been described both in detergent extracts of mitochondria
and after puriﬁcation of the ANT [52]. These results have been
interpreted within the framework of the PTP being formed by the ANT
and regulated by CyPD binding [53], possibly with the contribution of
VDAC as well [54]. As we have noted previously [55], in these
protocols several proteins other than the ANT bound to CyPD in a CsA-
inhibitable manner [52]. Notably, CyPD bound equally well to ANT
puriﬁed from rat liver and yeast, yet the permeability transition is not
inhibited by CsA in yeast mitochondria [56]. Our concerns about the
signiﬁcance of the CyPD–ANT(-VDAC) interactions in PTP regulation
are reinforced by the demonstration that ANT-null mitochondria still
display a CsA-sensitive permeability transition, although this requires
higher loads of Ca2+ and Pi [57], and that VDACs are dispensable for
PTP opening [58,59]. It should be noted that the identiﬁcation of the
ANT as a CyPD-binding protein was obtained by immunological
methods rather than by direct protein determination by sequencing
or mass spectroscopy [52]. Recent work has shown that the polyclonal
antibody used in these studies is not detecting ANT1 but rather the Pi
carrier [60], which has now been incorporated in the model of the PTP
proposed by the Halestrap laboratory [61], a working hypothesis that
in our opinion needs to be validated by more stringent tests.
Further regulatory interactions of CyPD are emerging in the
literature. A recent study has demonstrated the existence of a
complex mitochondrial chaperone network that involves Hsp90, its
related molecule TRAP-1, and CyPD [62]. CyPD bound to the complex
would no longer be available for PTP opening. CyPD displacement
Fig. 2. Interactions of CyPD with the lateral stalk of the F1FO ATP synthase. The ATP
synthase is depicted in the dimeric form, and the drawing highlights the possible site of
interaction of CyPD with the lateral stalk, possibly at subunit b. For further explanation
see text.
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could disable this protective network and reactivate the PTP with the
onset of mitochondrial depolarization, release of cytochrome c, and
massive cell death. Since the Hsp90–TRAP-1–CyPD interactions are
particularly prominent in tumor cells, this strategy has been suc-
cessfully used for their selective killing [62].
In keeping with previous results on the role of GSK-3 in PTP
regulation [63], we have recently found that a small fraction of ERK
associates to mitochondria, where it can be activated to phosphor-
ylate (hence inactivate) GSK-3 resulting in PTP desensitization. Of
note, CyPD could be co-immunoprecipitated with ERK2 and GSK-3,
and it was Ser/Thr phosphorylated. Phosphorylation correlated with
CyPD binding to GSK-3 and with PTP opening; and both events were
inhibited by the selective GSK-3 inhibitor indirubin-3′-oxime [64].
A recent study has demonstrated an interaction of CyPD with Bcl2
that could be displaced by CsA. In these protocols, addition of CsA
increased tBid-dependent release of cytochrome c from mitochondria
under conditions that did not cause the opening of the PTP, suggesting
a PTP-independent effect of CyPD (and CsA) that is relevant to
mitochondrial triggering of apoptosis [65]. Consistent with previous
results [66], CyPD overexpression made cells more resistant to apop-
totic stimuli, a ﬁnding that is difﬁcult to reconcile with a predominant
effect of overexpression on the PTP [65,66].
5. Cyclophilin D interactions with the F1FO ATP synthase
The F1FO ATP synthase is a 600 kDa multisubunit complex located
in the inner mitochondrial membrane whose catalytic part (F1) and
lateral stalk protrude into the matrix compartment where CyPD is
located, while the FO moiety and the remaining portion of the lateral
stalk are embedded into the inner membrane [67,68]. We recently
documented that CyPD interacts with the ATP synthase of bovine
heart mitochondria in protocols based on both blue native electro-
phoresis and immunoprecipitation of complex V after mild detergent
extraction [69]. Cross-linking with the cleavable bifunctional reagent
dimethyl 3,3-dithiobis-propionimidate, which reacts with the prima-
ry amines of two interacting proteins at an average distance of about
8 Å [70], demonstrated that CyPD forms a cross-linked complex with
OSCP, b, and d subunits in an apparent ratio of 1:1:1:1 [69], supporting
the interaction of CyPD with the extrinsic part of the lateral stalk. The
cross-linker also forms smaller complexes (such as b–d and b–OSCP)
[71], and so far we have been unable to resolve the CyPD direct
interactor(s) on the ATP synthase. Since only subunit b was detected
amongst CyPD-binding proteins in afﬁnity puriﬁcation-based proto-
cols (C. Baines, personal communication), we suspect that the direct
interaction of CyPD may occur with the surface area of subunit b
exposed to the mitochondrial matrix [67]. It is important to stress that
interaction of CyPD with the enzyme complex is favored by Pi and
competed by CsA. Importantly, CyPD binding has major functional
consequences, with a decrease of speciﬁc activity that can be reversed
by CsA-dependent CyPD displacement [69]. Whether this striking
analogy with Pi-dependent PTP regulation by CyPD [50] indicates a
link between the two processes remains a matter for future studies.
Fig. 2 illustrates the putative site(s) of interaction of CyPDwith the
lateral stalk of the F1FO ATP synthase, depicted here in the dimeric
form, which is considered the “building block” of higher order,
oligomeric forms of the enzyme that optimize its catalytic perfor-
mance; oligomeric forms are considered to represent the physiolog-
ical state of F1FO ATP synthase in the inner membrane [72,73]. There
is a wide variability in the angle formed by the monomers when they
associate into dimers [74], and it is tempting to speculate that CyPD
displacement by CsA may activate the enzyme by favoring the
formation of oligomers characterized by a higher activity. Conversely,
CyPD binding could switch the enzyme to a different oligomeric form
(i.e. a state with a different angle between monomers), with lower
catalytic activity [69]. Finally, it should be mentioned that thestimulatory effect of CsA is lost in Ppif−/− mitochondria, indicating
that it is mediated by CyPD, while assembly of the ATP synthase is
unaffected by CyPD ablation [69].6. Cyclophilin D in disease
Ppif−/−mice do not display an overt disease phenotype [46–49]. In
a number of independent laboratories, CyPD-null mice were born at
the expected Mendelian ratios [46–49] and were apparently identical
to wild-type, Ppif+/+ C57BL/6 animals, ﬁndings that indicate that
CyPD is dispensable for embryonic development and viability [47]. It
is possible that lack of a phenotype at birth may be due to adaptive
responses whereby the decreased sensitivity of the PTP to Ca2+ is
bypassed by compensatory mechanisms that are not detectable in
isolated mitochondria. It should also be noted that the physiological
role of CyPD may change during development, as neonatal Ppif−/−
mice are more sensitive to ischemia–reperfusion injury of the brain
[75] rather than more resistant as are adult mice [49,75]. However,
Ppif−/− mice display increased anxiety, facilitation of avoidance
behavior, and they develop adult-onset obesity independent of food
and water intake [76] suggesting that they may develop speciﬁc
phenotypes with aging. It should also be recalled that CyPD
overexpression desensitized cells from apoptotic stimuli, indicating
that CyPD may also play a role as a cell survival-signaling molecule
acting on targets other than the PTP [65,66].
CsA and its non-immunosuppressive analogs MeVal-4-CsA,
NIM811 and Debio 025 have been used in disease paradigms where
the PTP has been causally implied such as ischemia–reperfusion injury
of the heart and brain, TNF-α-dependent fulminant hepatitis, and
collagen VI myopathies (reviewed in [42,77]). As should be apparent
from the preceding paragraphs, the interpretation of these results is
not straightforward because (i) all CyPs, not only CyPD, are likely
inhibited to varying degrees by these drugs; (ii) the recent ﬁnding
that Drp1 dephosphorylation depends on calcineurin [28] demands a
reinterpretation of the protective effects of CsA in many animal
models of human disease since CsA's mitochondrial effects may in
part depend on inhibition of Drp1-mediated ﬁssion; and (iii) the PTP
is not directly affected by CsA but rather desensitized through the
inhibitory effects of Pi, and the PTP is insensitive to CsA if the Pi
concentration is not high enough [50]. The only models that allow
conclusions to be made on the role of CyPD in disease are those based
on the genetic ablation of CyPD (Ppif−/− mice), with the clear
Table 1
Role of CyPD in mouse disease models as assessed in Ppif−/− animals.
Disease model Effect Reference(s)
Heart ischemia–reperfusion Protection [46,48]
Brain ischemia–reperfusion
Adult Protection [49,75]
Neonatal Worsening [75]
Autoimmune encephalomyelitis Protection [86]
Mutant amyloid precursor protein mice
(Alzheimer's disease)
Protection [88]
Superoxide dismutase 1 G93A mutant mice
(amyotrophic lateral sclerosis)
Protection [87]
Scgd−/− (muscular dystrophy linked to
sarcoglycan deﬁciency)
Protection [99]
Lama2−/− (muscular dystrophy linked to
laminin deﬁciency)
Protection [99]
Col6a1−/− (muscular dystrophy linked to
collagen VI deﬁciency
Protection [96]
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the PTP, in the considered disease paradigm.
Convincing evidence obtained in adult Ppif−/−mice causally links
CyPD to ischemia–reperfusion injury of the heart [46,48] and brain
[49,75], as infarct size was reduced in CyPD-null adults compared to
wild-type or littermate controls. These studies corroborate the
conclusions of previous studies based on the use of CsA in ischemic
isolated hearts [78] and in infarcted patients [79], in brain damage by
hypoglycemia [80], hyperglycemia [81], middle cerebral artery
occlusion [82,83], and traumatic injury [84,85]. Ppif−/− mice
displayed a striking resistance to development of axonopathy in a
model of autoimmune encephalomyelitis [86], and to disease
progression after crossing with superoxide dismutase 1 mutant
mice [87], suggesting that CyPD-dependent mechanisms may be
critical in the neurodegenerative aspects of demyelinating and motor
neuron diseases. Ablation of CyPD has also been shown to substan-
tially improve learning, memory and synaptic function in a mouse
model of Alzheimer's disease, where it also alleviated reduction of
long-term potentiation mediated by the amyloid β peptide [88].
The best characterized case involving CyPD in pathology in vivo is
represented by collagen VI diseases [89], a set of genetically
heterogenous conditions that cause Bethlem myopathy [90], Ullrich
congenital muscular dystrophy [91,92] and myosclerosis [93] in
humans. Following the discovery that the mouse model of the disease
(Col6a1−/− lacking collagen VI [94]) has a striking mitochondrial
involvement in affectedmuscles that could be curedwith CsA [95] and
Debio 025 [32], we have recently shown that Ppif−/− Col6a1−/−mice
lacking both CyPD and collagen VI are indistinguishable from syngenic
wild type mice [96], providing a clear proof of principle for the causal
involvement of CyPD in the development of the disease that matches
the promising results obtainedwith CsA in patient cultures [97] and in
a pilot trial [98], and with the non-immunosuppressive CyP inhibitor
Debio 025 in the collagen VI myopathic mouse [32]. Although the
therapeutic outcome was less dramatic, these results are matched by
those obtained in Ppif−/− Scgd−/−mice, which showedmarkedly less
dystrophic disease in both skeletal muscle and heart than Scgd−/−
mice lacking δ-sarcoglycan [99]. In addition, Ppif−/− Lama2−/− mice
exhibited a signiﬁcantly extended survival compared to Lama2−/−
mice and treatment of the mdx mouse model of Duchenne muscular
dystrophy with Debio 025 resulted in markedly less dystrophic
disease [99]. The mouse disease models in which the effects of CyPD
ablation have been investigated are summarized in Table 1.7. Conclusions
We think that understanding the pathophysiology of CyPD will
provide novel perspectives to the development and use of CyPinhibitors of increasing speciﬁcity in CyPD-dependent diseases. In
addition, the emerging complexity of the mitochondrial effects of
CyPD (hence of CsA) should induce some caution in interpreting the
results obtained with CyP inhibitors and CyPD ablation as solely
resulting from modulation of the PTP.
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